Editorial: Accelerating Innovations for Enhanced Brain Health. Can Artificial Intelligence Advance New Pathways for Drug Discovery for Alzheimer's and other Neurodegenerative Disorders?
- PMID: 36641602
- PMCID: PMC12275707
- DOI: 10.14283/jpad.2023.1
Editorial: Accelerating Innovations for Enhanced Brain Health. Can Artificial Intelligence Advance New Pathways for Drug Discovery for Alzheimer's and other Neurodegenerative Disorders?
References
-
- Van Dyck C, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9–21. 10.1056/NEJMoa2212948 PubMed PMID: 36449413, Jan 5. - DOI - PubMed
-
- Sims J, et al. Donanemab in Early Symptomatic Alzheimer Disease. JAMA. 2023;330(6):512–527. 10.1001/jama.2023.13239 PubMed PMID: 37459141, Aug 8. - DOI - PMC - PubMed
-
- Sperling R, et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. N Engl J Med. 2023;389(12):1096–1107. 10.1056/NEJMoa2305032 PubMed PMID: 37458272, Sep 21. - DOI - PMC - PubMed
-
- Sperling R, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367–385. 10.1016/j.jalz.2011.05.2351 PubMed PMID: 21784348, PMCID 3693547, Jul. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical